Compare Goldman Sachs Physical Gold ETF (AAAU) vs ResMed Inc. (RMD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Goldman Sachs Physical Gold ETF vs ResMed Inc. — how do they compare? Goldman Sachs Physical Gold ETF trades at $40.18, while ResMed Inc. trades at $205.9 (market cap $31.88B). The key difference: ResMed Inc. pays a 1.09% dividend while Goldman Sachs Physical Gold ETF pays none, and Goldman Sachs Physical Gold ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| AAAU | RMD | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $53.21 | $293.73 |
52-Week Low | $32.29 | $182.82 |
Market Cap | — | $31.88B |
Enterprise Value | — | $31.06B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAAU, a US-listed gold-focused investment vehicle, trades at $41.04 with a 1.01% daily gain. Technical indicators show a bearish bias with moving averages signaling selling pressure, while oscillators remain neutral. The stock faces resistance at $41 with support at $40. Recent gold market dynamics show central bank accumulation and analyst price targets ranging from $4,500-$5,500 per ounce for the underlying commodity.
Gold's structural tailwinds from central bank demand and inflation hedging support long-term upside, though near-term headwinds include Fed policy uncertainty and dollar strength. The stock offers exposure to gold's safe-haven appeal but remains vulnerable to interest rate volatility and technical resistance levels.
ResMed (RMD) trades at $219.75, up 4.83% on the day, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company reported robust fundamentals with 2025 revenue of $5.15B and net income of $1.40B, supported by a 27.44% net margin. Recent strategic moves include the sale of MatrixCare for $490M and the acquisition of Noctrix Health, sharpening focus on core sleep and respiratory care markets.
Outlook remains positive with a consensus price target of $267.33 implying 21.6% upside, though risks include competitive pressures and integration challenges from recent M&A. The stock's current valuation at 21.06 P/E appears reasonable given growth prospects, but investors should monitor execution on guidance and market share retention amid emerging threats like GLP-1 drugs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Physical Gold ETF
AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.
Read more on AAAU →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
